Literature DB >> 23695554

The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target.

Carla Boccaccio1, Paolo M Comoglio.   

Abstract

The MET oncogene, a crucial regulator of the genetic program known as "invasive growth" or "epithelial-mesenchymal transition," has recently emerged as a functional marker of glioblastoma stem cells. Here, we review findings that associate MET expression and activity with a specific, genetically defined glioblastoma stem cell subtype, and data showing how MET sustains the stem cell phenotype in glioblastoma and other tumors. Finally, we discuss issues related to identification of tumorigenic clones driven by MET in the context of genetically heterogeneous tumors and strategies aimed at eradicating cancer stem cells. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695554     DOI: 10.1158/0008-5472.CAN-12-4039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells.

Authors:  Jing Zhang; Cang Liu; Ruiguang Hou
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

Review 2.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.

Authors:  Yiru Zhang; Trang T T Nguyen; Enyuan Shang; Angeliki Mela; Nelson Humala; Aayushi Mahajan; Junfei Zhao; Chang Shu; Consuelo Torrini; Maria J Sanchez-Quintero; Giulio Kleiner; Elena Bianchetti; Mike-Andrew Westhoff; Catarina M Quinzii; Georg Karpel-Massler; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin
Journal:  Cancer Res       Date:  2019-11-06       Impact factor: 12.701

Review 4.  Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase.

Authors:  Hang-Ping Yao; Xiang-Min Tong; Ming-Hai Wang
Journal:  Ther Adv Med Oncol       Date:  2021-04-03       Impact factor: 8.168

Review 5.  Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.

Authors:  Elena Anghileri; Anghileri Elena; Melina Castiglione; Castiglione Melina; Raffaele Nunziata; Nunziata Raffaele; Carlo Boffano; Boffano Carlo; Vittoria Nazzi; Nazzi Vittoria; Francesco Acerbi; Acerbi Francesco; Gaetano Finocchiaro; Finocchiaro Gaetano; Marica Eoli; Eoli Marica
Journal:  Neurosurg Rev       Date:  2015-07-28       Impact factor: 3.042

6.  miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.

Authors:  Fotini M Kouri; Carissa Ritner; Alexander H Stegh
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment.

Authors:  Jakub Godlewski; Anna M Krichevsky; Mark D Johnson; E Antonio Chiocca; Agnieszka Bronisz
Journal:  Neuro Oncol       Date:  2014-10-09       Impact factor: 12.300

8.  The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Authors:  Martijn P Lolkema; Hilde H Bohets; Hendrik-Tobias Arkenau; Ann Lampo; Erio Barale; Maja J A de Jonge; Leni van Doorn; Peter Hellemans; Johann S de Bono; Ferry A L M Eskens
Journal:  Clin Cancer Res       Date:  2015-03-05       Impact factor: 12.531

Review 9.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

10.  miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.

Authors:  Fotini M Kouri; Lisa A Hurley; Weston L Daniel; Emily S Day; Youjia Hua; Liangliang Hao; Chian-Yu Peng; Timothy J Merkel; Markus A Queisser; Carissa Ritner; Hailei Zhang; C David James; Jacob I Sznajder; Lynda Chin; David A Giljohann; John A Kessler; Marcus E Peter; Chad A Mirkin; Alexander H Stegh
Journal:  Genes Dev       Date:  2015-04-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.